Guido de Boer
Analyst · Intermonte
Thank you for opening this call, and welcome all to the half year 2026 results call for Exor. Two main highlights that we would like to present to you today. We announced last year that we will progress with simplifying our portfolio, and we've progressed at speed with doing that. The most sizable one, Iveco, you've followed closely where earlier in the half year, the sale of the defense business completed to Leonardo. Also a few weeks ago, Tata formally launched its tender offer for Iveco with closing to happen in 2 months. Also during the period, we completed the divestments of GEDI, Lifenet and NUO. I'm pleased to tell you that last days, we signed an agreement to sell our stake in Welltec, where we've owned the company through a business cycle, managing to run that business in a very well way with a price which will be substantially in line with what we put in our fair value balance sheet, which returned a MOIC of 2.4x, and we expect that to close in the first half 2027. That leaves us in an extremely strong position in turbulent times and leaves us in a good position to benefit from those turbulent times with a balance sheet that is extremely solid with EUR 4 billion of deployable cash approximately. To give you the bridge of that, we started the year of EUR 1.4 billion of cash. The proceeds from these divestments and some other divestments like reinsurance vehicles and distributions from venture arm deliver around EUR 2.7 billion of proceeds. Then with some net cash inflow from dividends and some capital calls we make for Lingotto, we'll end up with approximately EUR 4 billion of cash, of which we'll use EUR 0.5 billion in the buyback to execute in 6 months, and we'll speak a bit further about that later. Moving on to the key figures. During the period, our NAV declined by EUR 1.2 billion. We'll go into the detailed sources of changes from. While our loan-to-value strengthened quite a bit, obviously, with the increase in cash position. NAV per share fundamentally moved in line with our NAV as we did not buy back in the period. Our total shareholder return was below that because of the widening of discount journey. Composition of our portfolio changed on a few important items. Ferrari strengthened a bit from 32% to 34%. An important mover was CNH as well with a very strong performance in the period moved from 8% to 10% and obviously, also cash up to 6% during the period. If we then move to the breakdown of the change in GAV. There's a lot of numbers on this slide. The key one that explains the performance in this period is the change in value of listed company. We'll break down all the other buckets in detail. We want to be extremely transparent and show you all the levers of performance. We'll dive into that a bit further, but all of them led in the period, an increase from cash and cash equivalents from EUR 1.4 billion to EUR 2.2 billion, as mentioned, from EUR 300 million of investments largely behind the commitment Lingotto, around EUR 0.5 billion of disposals, the dividend we did and in other changes, EUR 676 million is the dividend inflow that we had less expenses. If we then move to the core bucket of investments that we have are listed companies. There you see the key driver of our performance was a strong decline in the share price of Stellantis during the period. The other 3 big companies all performed well with a notable mention for CNH. Iveco seems like a weak performer here. I would like to note that they distributed EUR 427 million of special dividend following the divestment of Leonardo. So for TSR, they show a strong green performance. We then present Clarivate were weak during the period. Via Transportation, which recently IPO-ed and they showed the similar trends of many U.S. tech companies that IPO-ed and weakened and have now since rebounded and is underlying strong results. If we then move on to unlisted companies, we disposed in the period GEDI and Nuo. After the period, we also sold Lifenet and Welltec, as I just mentioned. In total, around EUR 900 million of reduction of these unlisted companies and shifting more to a listed portfolio. The change in value, you see Institut Merieux, we'll speak later also about the direct holding in bioMerieux because the change in value of Institut Merieux largely driven change of the listed bioMerieux. Then moving to Lingotto and others. The intersection fund declined by EUR 370 million approximately. You might recall that last year, they went up EUR 1.2 billion. This is a logical volatility that we have in the market and I'm very confident given that they've never had a down year before, and they also drive to positive in these months. Lingotto Horizon was a good positive surprise where they have one investment in their portfolio, which saw a unicorn round and because we're one of the early investors that shows a very nice uplift value of that portfolio and the others moved steadily during that period. The investments we did were existing commitments for Horizon Innovation and Mosaic, and we invested in a very promising new hedge fund talent that's starting a new hedge fund with capital of EUR 200 million that's deployed in this period. Then we have the bucket of other assets, which before -- at the start of the period amounted to EUR 2.3 billion. We've been disposing quite a bit of assets in that category as well, and that's an ongoing process we plan to do. Key proceeds in the funds managed by third parties were EUR 55 million of reinsurance vehicles still left over from the PartnerRe disposal and EUR 38 million of distributions from Ora Global, the former Exor Ventures. Other assets were loans extended to GEDI and as part of the sale of GEDI were also. On the changes in value, also on the venture capital arm, they've made investments in some of the early AI companies, both in AI business themselves as well as in infrastructure. These all look to be unicorn investments, and that's driving a strong upward revision of the valuation of Ora Global. Listed companies down by EUR 237 million, EUR 180 million of that is related to bioMerieux and also Forvia on the back of the weakness in automotive, like I mentioned earlier. Stellantis was down 50% -- 60% the majority of change. That's for -- of the performance of our portfolio. I'm gladly answering questions. As I mentioned, the change in cash and cash equivalents, the breakdown I showed you at a high level before, EUR 861 million of dividends. We received a bit more of dividends, but we chose to take half of the dividend of Philips in shares, but that you won't see here in the cash and cash equivalents, but that explains the bridge between dividends and the dividend actually received. The disposals you see here that we just mentioned, investments and shareholder distributions equal dividends in this period. Given our sizable cash position, we also repaid one of our private placements just to make sure we treat our investment interest returns as efficiently as possible, and these borrowings were carrying a higher interest rate than our cash position. That's why we repaid debt ending with EUR 2.2 billion of cash last year. On the debt side, not much to report as I like it, being prudent on our debt position. So we have a debt position of EUR 3.7 billion, in line with what we had last year. You maybe see a bit of movement in other financial liabilities of EUR 140 million. That's just the timing of an FX transaction we did, which started at the end of the period and completed on the first day of July. That accounting entry, the bottom line number is EUR 3.7 billion. We have no redemptions anymore in 2026 nor in 2027. So in these turbulent times on the debt capital markets, fully funded on that side and first redemption to follow in 2028 with a very well spread out maturity profile for the coming next 12 years. That said on the debt side. Let me now turn to the capital allocation decision we took in the Board yesterday, doing a EUR 500 million on-market buyback, and we'll execute that in the next 6 months. You'll see also in the announcement that we are very explicit that both because the shares trade at a substantial discount to our NAV and don't reflect our assessment of the intrinsic value of our portfolio, we made this decision. We also said before, we do this because it's at a substantial discount as our NAV because we feel that this is a good resource allocation, investing at our portfolio, which we like at half of the cost is an investment that makes a lot of sense. We also chose to make the statement a bit stronger because I think we're actually in a triple whammy situation of the discount is at a very high level, 56% is a long time that we reached that. Our companies are at depressed levels, and we have a cash position that is well utilized. We feel this is part of our toolbox, but also a part of our ongoing toolbox that we continuously evaluate to do. It's not an opportunistic transaction, and we also chose not to do this as a tender offer, but an on-market program, which has started today and which will continue until the full year results in 6 months. It's important for us because we are committed to driving NAV per share growth as we've already done, outperforming both on an absolute and relative basis. As I mentioned, buybacks are and will remain a critical part of our [ commitment ]. So with those closing remarks, I would love to hand it over to Q&A.